With respect to emerging therapies, improved efficacy is the most desirable attribute for emerging therapies in mCRPC, but sustained effects and long-term safety are also critical. On average, surveyed urologists more than oncologists prefer oral formulations and therapies that do not require monitoring. Surveyed physicians are more familiar with Algeta/Bayer HealthCare's radium-223 and Bristol-Myers Squibb's Yervoy than they are with other therapies in development for mCRPC. Surveyed physicians rate radium-223—which has been filed with the FDA and EMA, and granted priority review by the FDA—as the therapy in which they are most interested.TreatmentTrends ® Prostate Cancer is a syndicated report designed to provide a view of the current and future management of prostate cancer based on primary research fielded with 50 urologists and 50 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Xtandi and potential launch of radium-223 through its LaunchTrends ® studies.
Despite The Recent Availability Of Xtandi, Zytiga Continues To Dominate The Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According To Surveyed U.S. Oncologists And Urologists
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts